Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Epistemonikos ID: ccd3c182e80f3d7264dbfd5dcf934ad1f483ea32
First added on: May 07, 2024